text: Thromboprophylaxis in COVID 19 Rationale and considerations The Corona Virus Disease 2019 COVID 19 pandemic is associated with a very high incidence of thrombotic complications The exact mechanisms for this excess risk for clots have not been elucidated although one of the often quoted pathophysiological entity is immunothrombosis Recognition of thrombotic complications early on in this pandemic led to an over explosion of studies which looked at the benefits of anticoagulation to mitigate this risk In this review we examine the rationale for thromboprophylaxis in COVID 19 with particular reference to dosing and discuss what may guide the decision making process to consider anticoagulation In addition we explore the rationale for thrombosis prevention measures in special populations including outpatient setting pregnant females children those with high body mass index and those on extracorporeal membrane oxygenation 